Announcements Trials
Browse Landscape

Phase

Phase 2 126Phase 1 67Phase 1/2 50Phase 3 38Phase 4 4Phase EARLY_PHASE1 3Phase 2/3 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Waldenstrom Macroglobulinemia 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × ibrutinib × Clear all
NCT04061512 2024-05-10

RAINBOW

University College, London

Phase 2/3 Recruiting
148 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT02801578 2020-02-27

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

M.D. Anderson Cancer Center

Phase 2/3 Completed
11 enrolled 7 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03642236 2018-08-22

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
122 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡